Bioorganic and Medicinal Chemistry Letters (2019)
Update date:2022-08-04
Topics:
Trzoss, Michael
Covel, Jonathan A.
Kapoor, Mili
Moloney, Molly K.
Soltow, Quinlyn A.
Webb, Peter J.
Shaw, Karen Joy
Fosmanogepix (APX001) is a first-in-class prodrug molecule that is currently in Phase 2 clinical trials for invasive fungal infections. The active moiety manogepix (APX001A) inhibits the novel fungal protein Gwt1. Gwt1 catalyzes an early step in the GPI anchor biosynthesis pathway. Here we describe the synthesis and evaluation of 292 new and 24 previously described analogs that were synthesized using a series of advanced intermediates to allow for rapid analoging. Several compounds demonstrated significantly (8- to 32-fold) improved antifungal activity against both Cryptococcus neoformans and C. gattii as compared to manogepix. Further in vitro characterization identified three analogs with a similar preliminary safety and in vitro profile to manogepix and superior activity against Cryptococcus spp.
View MoreYuan Shi(SuQian)Biotechnology Co.,Ltd
website:http://www.yuanshibio.com
Contact:+86-527-84226672
Address:jiangsu suqian
Suzhou Credit International Trading Co., Ltd
Contact:+86-512-65398039
Address:Qingdeng, Hightech. District, Suzhou
ShangHai Ruiyi Medical Technology Co.,Ltd.
Contact:+86-21-54718086
Address:No951 Jianchuan RD,Minhang District
Contact:+86-0592 5353131
Address:No.56 Guani Road Software Park 2,Siming District
Yangling Ciyuan biotech Co., Ltd.
Contact:86-15802970736
Address:2-1804, International Park Mansion, No.2, South Fengdeng Road, Lianhu District
Doi:10.1055/s-0036-1588422
(2017)Doi:10.1021/jo01050a549
(1962)Doi:10.1002/chem.200903158
(2010)Doi:10.1016/j.tet.2008.11.103
(2009)Doi:10.1021/acs.orglett.0c04114
(2021)Doi:10.1016/j.bmcl.2007.01.065
(2007)